We monitored long-term (median 11 months) concentrations of platelet serotonin and urinary serotonin, 5-hydroxyindoleacetic acid, and seven catecholamine metabolites in 44 patients with carcinoid tumors. Tumor serotonin and catecholamine contents (11 patients) and urinary histamine and N-methylhistamine (15 patients) were determined. Consistently increased concentrations of indoles, notably platelet serotonin, were observed in 96%, 43%, and 0% of patients with mid-, fore-, and hindgut carcinoids, respectively. Urinary dopamine metabolites, notably 3-methoxytyramine, were consistently increased in 38%, 20%, and 7% of patients with mid-, hind-, and foregut carcinoids, respectively. For urinary norepinephrine/epinephrine metabolites, notably normetanephrine and metanephrine, these data were 33%, 20%, and 14%, respectively. Midgut carcinoid tumors had the highest serotonin contents, whereas concentrations of catecholamines were independent of primary localization. There was no consistent relation between biogenic amine contents in tumors and urinary excretion of the amine metabolites. Occurrence of carcinoid syndrome was related to increased serotonin production rate. Increased histamine production is not an important feature in patients with lung carcinoids or livermetastasized ileum carcinoids. 
The APUD ( and prostaglandins have been implicated in the etiology of the cardnoid syndrome symptoms (6).
On the basisof their confinement to the APUD system, additional production of catecholamines and histamine by carcinoid tumors is conceivable. Aromatic L-amino acid decarboxylase (EC 4.1.1.28) not only catalyzes decarboxylation of 5 (20) . Aromatic L-amino acid decarboxylase also de- carboxylates histidine but has a lower affinity for histidine than for 5-HTP and L-DOPA (21) . Increased production of (notably) DA was found in patients with serotonin-producing carcinoid tumors (16 were determined in enzymatically hydrolyzed urine samples, with use of capillary gas chromatography with flame ionization detection, according to our previously described method (27 To qualii' as having increased concentrations of a single analyte according to the first criterion, a patient had to exhibit at least one value above the upper limit of the reference range when only two data points were available, or at least two abovenormal values when more data were available. To qua!-ify as having increased values according to the second criterion, a patient had to exhibit consistently increased concentrations for that analyte. Concentrations of analyte groups-"indoles" (platelet serotonin; urinary 5-HIAA and serotonin), "DA metabolites" (urinary HVA, DOPAC, and 3-MT), and "NE/E metabolites" (urinary VMA, MHPG, NM, and M)-were considered increased when at least one of the analyte members of the group met the above criteria.
Results
Clinical characteristics. for the study group of 44 carcinoid patients, together with the upper limits of the respective reference ranges. For indoles, the data were calculated from a median number of 6 assays (range 1-55) per patient; for catechohamines,the median number of assays per patient was 4 (range 1-35). The median follow-up period per patient was 11 months (range 1 day-5 years). Omission of data becauseof treatmentsurgical debulking or complete tumor removal-was (Table 2) . Urinary 5-HIAA of patients with midgut carcinoids was significantly higher than that of patients with fore-and hindgut carcinoids. Urinary serotonin excretion was greatest in midgut carcinoid patients, and differed significantly between fore-and midgut carcinoid patients.
Although median values and upper limits of urinary DA-metabolite excretion were highest in midgut carcinoid patients, no significant differences were found between the three subgroups. Subgroup differences between urinary excretion of NE and E metabolites were not significant either. 3; nos. 5,6,8,9, and 10) . On the other hand, normal urinary catecholcimineswere found in four patients with high tumor catecholamine contents (nos. 1, 3, 4, and 7 (Table 4) shows that, of all analytes, platelet serotonin is the most sensitive and consistently increased marker during long-term monitoring, notably for tumors originating from fore-and midgut. Data from the small number of patients with hindgut carcinoids suggest that serotonin production by these tumors is not only lower (Table 2 ) but also less consistent during long-term follow-up (Table 4) . For the clinical chemical diagnosis of hindgut carcinoids, it seems appropriate to repeat indole analyses over an extended period. These findings confirm and extend our previous report on pretherapeutic results for 30 patients from the present study group (8) . For the sake of simplicity we consistently used the term platelet serotonin in this study to refer to the serotonin concentration in platelet-rich plasma. The correct term, however, should be "apparent platelet serotonin" because, as we showed in carcinoid patients with increased serotonin production rate, the serotonin in platelet-rich plasma is not necessarily confined to platelets.
Unnary Catecholamines
Results from urinary catecholAmine metabolite analyses (Tables 2 and 4, Fig. 1) indicate that catecholamine production is frequently increased in patients with carcinoids, especially in those with midgut carcinoids. The number of reports on this subject is small (16, 22-24,  38-40) . In a study of 64 biopsy-proven carcinoid patients, Feldmrn (16) measured urinary excretion of free catecholamines, HVA, and plasma catecholamines.
In the 45 patients with serotonin-secreting carcinoid tumors, he found that 27%, 15%, and 0% had increased urinary free DA, NE, and E, respectively; 18% had increased excretion of HVA, and in 5 of 14 patients (35%) plasma DA was increased.
The 19 patients with non-
serotonin-producing carcinoid tumors did not show evidence of excessive DA production. On the other hand, increased urinary free NE, but not E, was observed in patients with both serotonin-secreting and -nonsecreting carcinoids and in patients with miscellaneous tumors.
The present study confirms frequently increased urinary DA metabolites and less frequently increased NE/E metabolites in carcinoid patients. However, as shown in Fig. 1 , we also found increased urinary catecholaxnine metabolites (originating from both DA and NEIE) in two patients with non-serotonin-producing carcinoids (nos. 9 and 10, Fig. 1 ). For the urinary excretion of catecholamine metabolites during follow-up, our data for sensitivities indicate that, in patients with foreand midgut carcinoids, increased production of catecholamines is less consistent than that of indoles (Table 4) . The moderate increase in urinary catecholamine metabolites, notably NM and M (42) (43) (44) , in patients with carcinoid tumors may give rise to confusion in the laboratory diagnosis of catecholsmiiie-secreting tumors such as pheochromocytoma. amine storage capacity, catabolizing activity, and frequency of release may explain the lack of relationship between tumor amine content and urinary metabolite concentrations. Excessive histamine production is not an important feature in patients with lung carcinoids or liver-metastasized ileum carcinoids.
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